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 Malaria, a plasmodial disease, causes more than one million deaths per year and has 
a significant public health impact. Improved access to prompt treatment with 
effective antimalarial drugs need to be conducted for prevention of infection in high 
risk groups. However, the parasite as causal agent has exhibited a potential danger 
of wide-spread resistances. This warning has directed attention to the study of 
alternative methods of protection against the disease, among them is to do the 
immunization. A deeper understanding of the nature and regulation of protective 
immune mechanisms against this parasite will facilitate the development of much 
needed vaccines. Developing a malaria vaccine remains an enormous scientific,
technical, and financial challenge. Currently a vaccine is not fully available. Among 
the practical applications of radiobiological techniques that may be of considerable 
interest for public health is the use of ionizing radiation in the preparation of 
vaccines. Convincing data were reported that sporozoites of Plasmodium berghei 
irradiated with X- or gamma-rays, provide an antigenic stimulus effective to induce 
a protective immune response in mice and rats against subsequent sporozoite 
infection. Irradiated parasites are better immunogens than killed ones and although 
non-infective they are still metabolically active, as shown by continued protein and 
nucleic acid synthesis. There is a substantial number of data from human studies 
demonstrating that sporozoites attenuated by radiation are potent inducers of 
protective immunity and that they are safe and do not give rise to the asexual 
erythrocytic infections that cause malaria. This vaccine is relatively inexpensive to 
produce, easy to store, and transportable without refrigeration. A long-term effort 
and commitment to providing resources must be maintained and increased to 
achieve the goal of a malaria vaccine candidate where ionizing radiation as a tool to 
prepare is seemingly feasible.  




Malaria is the most important disease of 
human in the world. As a whole, it is estimated that 
500 million people are infected with the disease. 
This parasitic disease kills 2.7 million people across 
the world each year. In the past more than one-third 
of the total world populations were exposed to 
malaria infection and at least half the people who 
died from all causes were probably killed directly or 
indirectly by malaria [1]. This disease has a 
tremendous impact on human health and it is a 
major impediment for social and economic 
development of nations in malaria-endemic areas, 
particularly in sub-Saharan Africa and Asia. Malaria 
is also a major problem for young children and 
pregnant women [2]. The health implications of 
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malaria in tropical Africa are reflected in the 
exceptionally high mortality and morbidity rates in 
rural areas. In West Africa at least 10% of deaths 
below five years of age are due to malaria. While in 
unprotected rural communities the infant mortality 
rate from all causes, in which malaria plays a major 
role, may reach even 50%. The highlands of tropical 
Africa are occasionally swept by severe malaria 
epidemics, which sometimes cause as high as 25% 
mortality [1].  
Apart from tropical Africa, the disease is still 
endemic in large areas of the world including South-
East Asia (SEA). In this region, ten out of 11 
countries are malaria endemic. World Health 
Organization (WHO) estimates that of 40,213,000 
Disability Adjusted Life Year (DALYs) in the 
world, 2,390,000 are in Asia (SEA 1,874,000 
DALYs or 4.66%) [2]. Although Asia contributes 
only about 6% of DALYs in the world, but malaria 
causes high morbidity and mortality in the endemic 
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countries. The disease is deeply rooted in                         
the poor communities, affecting national 
development and takes away major share of               
health budgets. The average laboratory                
confirmed cases were reported around 2.5 million 
annually where as probable malaria cases                    
were around 20 million annually. An estimated               
of 1,326.5 million people, or 82.8% of                              
the total population of SEA Region, are at                      
risk of malaria. Out of which around                        
41.5% population at moderate to high risk of 
malaria, 41.7% are at low risk where as                 
remaining 16.8% of population free from malaria. 
About 95% of the populations with moderate                    
to high risk of malaria in SEA Region are                     
living in Indonesia, Myanmar and Thailand [3].  
According to the Department of Health                   
that figuring the Indonesian Health Profile                       
in 2004, malaria has spread almost uniform                    
in all parts of the country mainly in the                    
islands outside Java and Bali. It was estimated               
that 35% peoples or about 90 million populations 
were living in malaria risk areas [4]. However,               
the National Planning Agency claimed                             
that the malaria incident was decreased since              
2001, in part due to the implementation of 
Eradication Action on Malaria that started in               
April 2000. In Java and Bali the target number               
of malaria victims in 2002 was overed the                   
target of indicator of Indonesia Health 2010,                 
i.e. below 5 per 1000 peoples [5]. 
Improved access to prompt diagnosis                    
and treatment of malaria needs to be combined                
with a multi-prolonged approach to prevention               
that should include vector control, insecticide-
treated nets, and the use of drugs for                 
prevention of infection in high risk                             
groups (intermittent preventive treatment) [6,7]. 
However, the potential danger of wide-spread 
resistance of the vector to insecticides, and              
of drug resistance among plasmodia which                 
infect humans is steadily increasing and has         
recently been stressed repeatedly. These                
warnings have again directed attention to                         
the study of alternative methods of                        
protection against the disease, among them                      
to the immunization of population at                            
risk. Furthermore, because of the limitations                     
of diagnostic procedures based upon the                        
detection of the contributing parasites in                           
the blood, investigations have been intensified                
in recent years to develop immunobiological                 
tests and to evaluate them in individual cases           
as well as in epidemiological surveys,                           
and in determining the effects of control                          
and treatment [1,8]. 
MALARIA AND VACCINE 
 
Malaria infection begins when a plasmodium 
infected female Anopheles mosquito bites a person 
and injecting these parasites, in the form of 
sporozoites, into the bloodstream. Once in the body, 
plasmodium has a complex life cycle. After is 
inoculated by mosquito biting, it will invade 
hepatocytes, transform into liver stages, and the 
subsequent liver stage development ultimately 
results in the release of pathogenic merozoites. 
These merozoites released from the liver cells in 
vesicles where eventually disintegrate, freeing the 
merozoites to enter the blood phase. In the 
bloodstream, the merozoites invade red blood cells 
(erythrocytes) and multiply again until the cells 
burst. Some of the infected blood cells leave the 
cycle of asexual multiplication. Instead of 
replicating, the merozoites in these cells develop 
into sexual forms of the parasite, called 
gametocytes, that circulate in the bloodstream. 
When a mosquito bites an infected human, it ingests 
the gametocytes, which develop further into mature 
sex cells called gametes. The cycle of human 
infection begins again when the mosquito bites 




Fig. 1. Life cycle of Plasmodium sp. in the body of mosquito 
and infected host [9]. 
 
Vaccination is historically the most effective 
way to control infectious disease such as malaria. 
Vaccines are designed to stimulate the immune 
system to protect against micro-organisms such as 
viruses or bacteria, by introducing a small amount 
of the virus or bacteria into the body. When this 
foreign substance invades the body, the immune 
system activates certain cells to destroy the invader. 
If the body is re-invaded by the virus or bacteria in 
the future, the memory cells will be reactivated and 
respond faster and more powerfully to destroy the 
virus. It was suggested that active immunization 
may be of value in protection against some parasitic 
diseases, including malaria, and is mainly based on 
consideration of the natural history of the disease.  
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A deeper understanding of the nature of protective 
immune mechanisms against malarial parasite will 
facilitate the development of much needed vaccines 
[10]. The first vaccination was performed by 
Edward Jenner who had noticed that dairy maids 
who had had cowpox infection did not succumb to 
the deadly smallpox infection that was claiming 
many lives at the time. The body's immune system 
is comprised of two arms that are antibody-mediated 
immunity and cell-mediated immunity. All vaccines 
developed in the last 50 years probably protect by 
stimulating a potent antibody response. However, 
for pathogens that live within cells of the body, 
where antibodies can't reach, it is likely that               
cell-mediated immunity is required for protection. 
Examples of such pathogens include HIV and 
malaria. Each of these is a huge global health 
problem claiming millions of lives each year for 
which there is no effective vaccine. 
The development of a safe and efficacious 
malaria vaccine has remained an elusive goal for the 
past 80 years. However, recent years have witnessed 
a new impetus and the generation of conclusive 
evidence that effective immunity against 
Plasmodium falciparum infection, mild 
uncomplicated malaria, and severe disease can be 
induced through vaccination in children living in 
malaria-endemic areas. It is likely that the next 
decade will witness the first registration of a malaria 
vaccine. This vaccine is unlikely to provide 
complete protection, but it may become a useful tool 
to be added to the armory in the fight against 
malaria. Moreover, scientists exactly looking for in 
a malaria vaccine are that vaccine should require as 
few doses as possible to work and has to be cheap to 
make and administer. The vaccine should offer 
long-lasting, preferably life-long, protection against 
all parasite strains. Although it is the blood stage 
that causes clinical disease, an ideal vaccine would 
be a combination, able to work against multiple 
stages. As malaria is endemic in numerous 
developing countries, the vaccine would have to be 
stable in different temperatures and simple to 
administer. Ideally, vaccine use would use existing 
infrastructure used for infant immunization [11]. 
For about 25 years, scientists have tried to 
develop modern and recombinant `subunit' malaria 
vaccines which is actually difficult. Most vaccines 
are based on attenuated or inactivated whole 
pathogens or material derived directly from the 
infectious agent. An effective vaccine against                
P. falciparum malaria remains one of the great 
challenges of medicine. Despite over one hundred 
years of effort, hundreds of millions of dollars in 
research, lifelong sacrifice from dedicated 
physicians and scientists and many promising 
experimental vaccines, there is no marketed vaccine 
to alleviate one of the great infectious scourges of 
humanity [12]. The past few years have witnessed 
the appearance of a significant increase of resources 
devoted to the development of malaria vaccines. 
Lessons have been learned on different approaches 
to the clinical development plan for a vaccine 
candidate, including different clinical trial phases 
and endpoints and methods to conduct them. 
Improved understanding of mechanisms underlying 
naturally acquired immunity, definitions of surrogate 
markers of protection, including improved in vitro 
assays and animal models, and strengthened 
capacity in malaria-endemic countries to conduct 
clinical trials would accelerate the development of 
malaria vaccines. The impact of this vaccine and 
subsequent products will need to be evaluated under 
program conditions in the context of comprehensive 
malaria control activities. Deployment of a safe and 
effective malaria vaccine administered in early 
childhood could become a major public health tool, 
particularly in sub-Saharan Africa [13].  
Developing a malaria vaccine remains an 
enormous scientific, technical, financial, and 
political challenge. The plasmodium is a highly 
complex parasite, with a multi-stage life cycle, 
during which the parasite presents multiple antigens 
that show significant variability. The main hindrance 
to developing a vaccine is the choice of the antigen 
or antigens to be included. This process has often 
relied on the use of imperfect animal models, in 
vitro assays with significant limitations, and 
seroepidemiological assessments of naturally 
acquired immune responses in humans and their 
relationship to the risk of malaria infection or 
disease. Numerous associations between antigen-
specific immune responses and the risk of infection 
or disease have been described. However, an 
association between a given immune response and 
the risk of malaria does not mean that those 
responses play a role in protection, as previous 
exposure to the parasite and development of 
responses to multiple antigens, most of which are 
unlikely to be linked to protection and are simply a 
marker of exposure, become an important 
confounding factor [13].  
At present there are approximately 100 
candidates of malaria vaccine in development, 
including pre-erythrocytic vaccines, blood-stage 
vaccines, anti-toxic vaccines, and transmission-
blocking vaccines. Nevertheless, most of them are 
based on a small number of P. falciparum antigens 
[14,15]. Only a few candidates have entered clinical 
phase studies, and most are still in pre-clinical 
phases. The malaria community has understandably 
placed a major effort in the antigen selection process 
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as the key to the development of a malaria vaccine. 
However, the results of the RTS,S candidate vaccine 
have highlighted the critical role that formulation 
and adjuvant technology may play in the successful 
development of a product. This vaccine, based on 
the circumsporozoite antigen, had failed to provide 
protection in numerous trials [16,17], and following 
commonly held views, should have been abandoned 
a long time ago. However, formulation of that same 
antigen in a new adjuvant platform radically 
changed the outlook for this product, which has 
shown safety, immunogenicity, and induction of 
protection in challenge models with non-immune 
volunteers, hyper-immune adults, and semi-immune 
children living in malaria-endemic areas of Africa 
[16,18-20]. 
The overall results in human trials indicate a 
short duration protection. More recently 
RTS,S/AS02A vaccine has performed better in 
infants less than 1 year of age. Another example is a 
DNA vaccine using TRAP (thrombospondin-related 
adhesive protein) antigen with a string of T-cell 
epitopes using a prime-boost sequence with MVA 
(modified vaccinia virus Ankara) or FP9 which is 
attenuated pox virus followed by MVA as boosters. 
This induced high T-cell response and a substantial 
delay to parasitemia in sporozoite challenge studies. 
None of these results match the complete protection 
obtained with irradiated sporozoites in experimental 
animals and human volunteers [14]. Many 
researchers are developing a non-replicating, 
metabolically active, radiation-attenuated                     
P. falciparum sporozoite vaccine. When such 
sporozoites are injected intravenously into mice, 
they enter the liver, but do not develop further. 
Interestingly, when 25,000-50,000 of these 
knockout sporozoites are injected into mice using 
different prime-boost protocols, they protect the 
animals when infected with wild type sporozoites. 
This protection is seen even two months after 
vaccination. The vaccine is stage-specific, since 
blood stage parasites when injected develop 
normally. Protection is also seen when sporozoites 
are introduced through mosquito bites. Thus, proof 
of principle for a genetically altered whole-parasite 
based vaccine has been established [21,22]. 
One main obstacle in malaria vaccine 
discovery is the absence of sterilizing immunity 
during natural infection. The corresponding whole-
organism vaccines mimic an acute pathogen 
infection, which were known to function as a natural 
vaccination after the host immune system resolved 
the first infection. There is no such model of 
acquired immunity against the plasmodium parasite. 
Yet, a malaria vaccine will only become an efficient 
public health tool if it provides protection for 
several years with no more than three 
immunizations. One potential, yet challenging, 
solution to this problem may be the composition of 
vaccine strategies that aim at inducing protective 
immune responses against immunological silent 
plasmodium life cycle stages, i.e. those that are not 
the typical targets of naturally acquired immunity. 
Recent insights into the parasite biology and 
technological advancements open the possibility to 
explore such alternative vaccine strategies. 
Vaccine strategies against malaria is that 
natural transmission to the human host may be 
reduced by high titers of sporozoite-neutralizing 
antibodies that act prior to hepatocyte entry. In 
addition, vaccination with sporozoite antigens may 
induce cell-mediated responses to the infected 
hepatocyte. The progression of pathogenic blood 
stages can be reduced during the brief phase of 
merozoite entry into erythrocytes. P. falciparum-
infected erythrocytes adhere to endothelial cells in 
capillaries and the placenta through parasite-
encoded surface proteins that eventually lead to 
antibody recognition. Maturation of liver-stage 
schizonts and ookinete penetration of the mosquito 
midgut represent two immunology silent stages of 
the plasmodium life cycle. Genetically attenuated 
parasites elicit long-lasting complete protection in 
experimental models. These genetically defined 
parasites are inoculated as sporozoites and invade 
and transform normally, but arrest during 
subsequent liver-stage development. At this time 
they likely display protective antigens in the context 
of major histocompatibility complex (MHC) class I 
presentation that, in turn, activate interferon-c-
secreting effector T cells. Two partially redundant 
ookinete surface proteins, Pfs25 and Pfs28, 
constitute attractive targets for the development of 
transmission blocking vaccines. Targets for vaccine 
development include surface proteins or adhesion 
proteins of invasive stages [22].  
 
 
DEVELOPING VACCINE WITH NUCLEAR 
TECHNOLOGY 
 
Among the practical applications of 
radiobiological techniques that may be of 
considerable interest for public health is the use of 
ionizing radiation in the preparation of vaccines. 
Attempts of vaccine production by exposing 
various kinds of micro-organisms including 
viruses, bacteria and fungi, as well as unicellular 
and multicellular parasites to ionizing radiation 
have been reported in scientific periodicals from 
time to time. Radiation attenuated vaccines have 
been demonstrated to be an effective means of 
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controlling certain parasitic infections such as 
malaria. Although many parasitic diseases are 
known to produce a high degree of acquired 
immunity, it has been impossible in the past to 
reproduce this immunity using artificially prepared 
vaccines, the striking exception being the radiation 
attenuated vaccines. The successful use of irradiated 
plasmodium as a vaccine depends on finding a 
radiation dose which will significantly reduce the 
pathogenic effect of the larvae without seriously 
impairing their immunogenic power [23]. 
Gamma radiation is widely used by many 
researchers to inactivate parasite for the preparation 
of vaccines, instead of traditional heat or chemical 
methods of inactivation, appears to create a vaccine 
that is more effective than so-called "killed" 
vaccines against disease, and has the added 
advantage of a longer storage life than "live" 
vaccines. Irradiation is a technically simple process 
that retains structural features of the microbial 
pathogen without destroying the natural antigens or 
the intrinsic adjuvants. Therefore, a strong immune 
response is induced in the vaccinated host. 
Irradiation destroys the DNA, making the 
microorganism unable to replicate so it cannot 
establish an infection, but some residual metabolic 
activity may survive, so the irradiated 
microorganism can still find its natural target in the 
host. Vaccination with a freeze-dried powder 
formulation of the irradiated bacteria, a product with 
the potential to be easily and inexpensively stored 
and transported then reconstituted just before use, 
was also shown to protect mice against lethal 
infection [23]. In experiments with mice, the 
researchers in Infectious Diseases Section, VA San 
Diego Healthcare System USA demonstrated that a 
vaccine made with irradiated Listeria 
monocytogenes bacteria provided much better 
protection against disease than vaccine made from 
heat-killed bacteria. Irradiation is a technically 
simple process that retains structural features of the 
bacterial pathogen without destroying the natural 
antigens or the intrinsic adjuvants. Therefore, a 
strong immune response is induced in the 
vaccinated host. 
Since 1966, the International Atomic Energy 
Agency (IAEA), in collaboration with the Food and 
Agricultural Organization of the United Nations, has 
had a co-ordinated research programme on the 
application of nuclear techniques to human 
parasitology. It soon became obvious that the 
similarity of certain parasitic infections in man and 
animals as well as the existence of cross-infections 
would make it extremely difficult to keep any strict 
and unnatural species barriers. The apparent 
similarity, for instance, between human and animal 
trematodes like Trypanosoma and plasmodium 
clearly suggests the extension of these studies to 
human parasitic diseases. The recommendations of 
the meeting between IAEA and WHO several years 
ago urged these two international organizations that 
a co-ordinated collaborative research programme be 
initiated on the use of nuclear techniques in 
preparation of vaccines against human parasitic 
diseases, with the highest priority being given to 
malaria. There are essentially two distinct ways in 
which nuclear techniques can be employed in 
research performed under this co-ordinated 
programme : the use of ionizing radiation for 
attenuation of the parasitic organisms; and the use of 
radioisotopes as tracers in studies on the physiology 
of the parasites and on the host-parasite 
relationships. 
Subjects recommended for research using a 
more empirical approach are as follow : further 
immunization trials with radiation attenuated 
vaccines on various host-parasite systems with both 
homologous and heterologous combinations of 
immunizing an challenging antigenic variants; 
determination of optimum dosage of irradiated 
parasites; number of boosters; spacing of 
vaccination; characteristic, duration and species 
specificity of the protection; occurence of undesired 
side effects following vaccination; radiosensitivity 
of the parasites at their different stages of 
development; and optimum range of radiation doses 
to be applied for attenuation. 
Furthermore recommendations for basic 
studies those are to contribute to the general 
understanding of the host-parasite interactions in 
human parasitic infections and the physiology of the 
parasites include subjects such as: methods for 
labelling of parasites with radioactive isotopes and 
for determining the nature and location of their 
antigens; morphological and physiological 
alterations in parasites induced by irradiation; 
survival and localisation of irradiated parasites in 
the inoculated host; existence of natural antibodies 
against parasites; the relative role of cell mediated 
versus antibody mediated immunity in host defense 
mechanism; passive transfer of immunity into 
sublethally irradiated recipient animals; induction 
and/or selection of genetic mutant parasites that are 
less pathogenic and thus more suitable for 
vaccination; and metabolism of parasites and the 
essential requirements for their cultivation in vitro. 
In 1967, Nussenzweig reported that 
immunizing mice with radiation-attenuated 
Plasmodium berghei sporozoites protected them 
against challenge with fully infectious sporozoites 
[24]. This rodent study provided the impetus for 
human studies. During the 1970s, Clyde DF and 
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colleagues established that immunizing human 
volunteers with bites of irradiated mosquitoes 
carrying P. falciparum sporozoites in their salivary 
glands could protect volunteers against challenge 
with fully infectious P. falciparum sporozoites [25]. 
These studies demonstrated that a malaria vaccine 
offering sterile protective immunity was possible. 
However, the only way to produce sporozoites at 
that time was to infect a volunteer with                          
P. falciparum, treat the volunteer with doses of 
chloroquine to suppress but not eliminate the 
parasite, allow gametocytes to develop and then feed 
mosquitoes on the volunteer. 
Even if one could produce sporozoites in 
adequate numbers by this method, it was considered 
clinically, technically and logistically impractical to 
immunize large numbers of individuals with an 
irradiated sporozoite vaccine, in large part because 
the sporozoites had to be delivered alive, either by 
the bite of infected mosquitoes or by an intravenous 
injection, as was done with mice. Potential solutions 
to these problems, although not necessarily 
recognized at the time as being related to developing 
an attenuated sporozoite vaccine, were being 
reported. In 1975, a method for culturing P. 
falciparum in vitro was reported [26,27], followed 
by a method for producing gametocytes from these 
cultures in 1986 [28]. In 1986, it was reported that 
humans could be infected by the sporozoites 
produced in mosquitoes that had fed on these in 
vitro cultures [29]. There was therefore a way to 
produce sporozoites without the difficulties of in 
vivo production of gametocytes in humans.  
Convincing data were reported during the past 
few years that relatively small numbers of 
sprozoites of P. berghei irradiated with X- or 
gamma-rays, provide an antigenic stimulus effective 
to induce a protective immune response in both 
mice and rats against subsequent sporozoite 
infection, but not against infection with blood forms 
of the parasite. For protection of the animals against 
an infecting dose of blood forms, a vaccination is 
necessary with parasitized red blood cells that have 
previously been exposed to ionizing radiation. 
According to preliminary studies carried out in 
monkeys, the results on rodent parasites cannot be 
extrapolated to primate plasmodia, though, in one of 
the experiments a definite protection has been 
obtained with four intravenous inocula of infected 
and irradiated red blood cells. Further investigations 
with P. knowlesi have suggested that one of the 
reasons why irradiated parasites are better 
immunogens than killed ones is that, although non-
infective, they are still metabolically active, as 
shown by continued protein and nucleic acid 
synthesis. It has become evident that normal 
multiplication and infectivity of trypanosomes can 
be suppressed by a small fraction of the dose 
required to kill the parasites. Thus irradiation may 
enable one to take advantage of the special 
immunological properties of living parasites. At the 
same time, the pathogenic effects of a vaccine 
prepared from parasites with an unimpaired 
reproductive capacity would be obviated. In spite of 
this promising hypothesis, the research on the 
possible employment of radiation attenuation for the 
control of trypanosomiasis has been resumed only 
recently [30]. 
Large-scale production of attenuated parasite 
vaccine may indeed become feasible, because some 
challenges, such as sterility, cryopreservation, and 
route of immunization, have either already been met 
or are under active investigation [12]. Other 
roadblocks related to the safety and batch-to-batch 
variation of genetically undefined irradiated 
sporozoites have recently been removed in the 
rodent malaria model system by the generation of 
genetically attenuated parasites (GAPs) [21]. 
Although translation to the P. falciparum system 
may take several years, early human challenge 
studies with irradiated sporozoites indicate that 
complete attenuation of liver-stage development 
elicits protection to date the gold-standard in               
P. falciparum vaccine development. GAPs differ 
from gamma-irradiated sporozoites in their 
consistent production, genetic stability, and higher 
potency [31,32]. A fundamental issue is whether 
natural exposure to plasmodium transmission would 
boost GAP-induced immune responses. If this was 
the case a GAP vaccine would be feasible for 
individuals from malaria-endemic countries. 
Otherwise only short-term visitors would benefit 
and GAPs would fall into the category of 
‘boutique vaccines’. 
A critical focus of vaccine development 
process has been to determine the minimum dose 
of radiation that adequately attenuates all 
sporozoites, and thus ensures that the vaccine will 
not cause malaria. Researchers are also interested 
in determining the highest dose of radiation that 
leaves the sporozoites able to elicit optimal 
protective immunity. For this, Chattopadhyay R. 
et al. (2008) have studied in the Plasmodium yoelii 
rodent model system [33]. Exposure to 100 Gy 
completely attenuated P. yoelii sporozoites.            
They also demonstrated that immunization of 
mice intravenously with 3 doses of 750 P. yoelii 
sporozoite that had received 200 Gy, double the 
radiation dose required for attenuation, resulted in 
100% protection. These results support the 
contention that a radiation attenuated sporozoite 
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vaccine for malaria will be safe and effective at a 
range of radiation doses. 
Presently there is no malaria vaccine available 
to travellers or individuals living in malaria endemic 
areas. A recent promising vaccine to undergo 
clinical trials in Africa is the P. falciparum 
circumsporozoite (CS) protein construct with 
recombinant hepatitis particles (RTS,S). Previously, 
this vaccine induced 50-60% pre-erythrocytic 
protection against homologous P. falciparum 
challenge in naïve volunteers [16,34]. However, in 
Gambian adults, this vaccine did not induce similar 
patterns of immunity and protection was short-lived 
[18,19]. It could be argued that this vaccine, 
targeting the highly polymorphic CS antigen, 
worked as expected, since a heterogenous 
population of parasites exist in endemic areas. 
McConkey and colleagues recently reported highly 
encouraging results on the induction of substantial 
P. falciparum specific CD4 and CD8 T cell levels in 
naive humans using Prime-boost [35]. Such 
protocols, if combined with high selectivity in 
antigen and variant/conserved epitope inclusion, 
may help overcome the problems of variant-specific 
immune evasion. Indeed, the most potent vaccine 
for malaria endemic areas may prove to be a multi-
antigen, multi-stage combination.  
However, identification of new and conserved 
antigens alone may not be sufficient for a vaccine 
that is successful in malaria endemic areas, as acute 
malaria infection is associated with T cell 
immunosuppression with a variety of generalized 
immunological changes, some of which                           
are discussed above. An additional problem 
common to all vaccines is that in the field, they            
may preferentially re-stimulate pre-existing 
immunity induced by past infection with                      
a bias towards a specific, and not necessarily 
protective, cytokine secretion pattern. It is                   
hoped that as new vaccine approache and 
understanding of the mechanisms of immune 
evasion at the host parasite interphase                    
progress, elements of its design will provide an 




DOSE OF IRRADIATION AS CRUCIAL 
FACTOR 
 
The dose of radiation used to attenuate 
plasmodium is the most crucial factor. Therefore, to 
determine the dose of gamma-irradiation which 
will produce attenuated parasites without 
affecting the pre-erythrocytic and erythrocyte 
stabilities is the ultimate goal of many studies on 
irradiation vaccine. It is thought that the amount 
of radiation required to render the parasites non-
viable is about 150 Gy for an inoculum of certain 
number of parasites [12]. There is also evidence that 
exo-erythrocytic stages may be more susceptible to 
gamma-rays than are blood parasites. It means that a 
most important step is to determine minimum dose 
of irradiation required to adequately attenuate each 
sporozoite. 
Scientists in many parts of the world have 
created harmless versions of malaria-causing 
parasite by applying radiation technology, and are 
using them to create a new malaria vaccine that 
could be more effective than the ones already in 
existence. Researchers at the National Institute of 
Standards and Technology (NIST) in USA used 
their expertise to help Maryland-based biotech 
firm Sanaria Inc., which is creating the new 
vaccine, create these parasites. The researchers 
already have extensive knowledge relating to 
measuring the right doses of radiation for other 
procedures. The scientists from the NIST are going 
to continue to work with Sanaria Inc. and perform 
quality assurance tests to make sure that the dose is 
being given to the mosquitoes correctly [1].  
Decades ago, scientists had discovered that 
volunteers built up high levels of protection to 
malaria after being exposed to mosquitoes 
containing live, radiation-weakened parasites. Since 
then they had been striving to use vaccines based on 
whole living parasites. However, the developing 
technology for extracting weakened parasites from 
their mosquito carriers has introduced recently.               
In the manufacturing process, live mosquitoes 
containing the parasite are exposed to gamma rays. 
To ensure that the parasites are sufficiently 
weakened for the vaccine, yet remain alive, they 
must be exposed to a radiation dose of at least              
150 Gy, but not much more. The researchers have 
revealed that to be safe for human trials, all 
mosquitoes must get their minimum radiation dose 
of 150 Gy. NIST researchers will remain associated 
with the manufacturing of the vaccine by doing 
regularly scheduled quality-assurance tests to ensure 
the desired dose is being delivered to the 
mosquitoes. It is only at this dose that they can be 
sure that the parasites are weak enough for the 
vaccine, but are still alive [36]. 
Experiments conducted by Ferreira-da-Cruz 
et al. [37] in Brazil provide evidences that a 200 Gy 
gamma-irradiation is able to abolish the original 
replication of erythrocytic forms of the Palo Alto            
P. falciparum strain, probably by inactivating their 
infectivity. According to their data, 100 or 150 Gy 
irradiation doses were enable to inactivate the 
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parasite, despite the reduction of parasitemia, 
suggesting the existence of heterogenous plasmodial 
populations as concerns susceptibility to irradiation 
and pointing to the possibility that the same dose 
could inactivate parasites from other P. falciparum 
strains. Beside that, in view of the nonexistence of 
defense immune mechanisms in the in vitro culture, 
it is reasonable to suppose that the dose required to 
abolish infectivity in these conditions is higher than 
that expected to inactivate the parasite in vivo, fact 
that increases the safety of the proposed dose of 
irradiation. Nevertheless, studies of the effects of 
gamma-irradiation on the in vivo infectivity of                
P. falciparum in non human primates are necessary 
to clarify this question. If proven to be safe, this 
methodology could rescue blood bags eventually 
contaminated with P. falciparum, with low costs 
and no risk of inducing transfusional malaria, and 
help solving the problem of the chronic deficit of 
blood in malaria endemic areas. 
Research on malaria in BATAN is being 
focused on the development of irradiation vaccine 
that was started in 2005 and included in Main Focus 
through Research Project entitled “The Controlling 
Infectious Diseases with Nuclear Technology” [38]. 
In preliminary step of research the determination of 
optimal gamma rays dose for attenuating parasite to 
get basic material of vaccine was done by using              
P. berghei as model. In erythrocytic stage, the 
gamma attenuated parasite was effective in eliciting 
immune response and supressing its infectious 
pattern as approved by longer prepatent periods, the 
lower percentage of parasitemia and less mortality 
of mouse compared to those of non irradiated 
plasmodium. Irradiation dose of 75-125 Gy were     
not enable to attenuate plasmodium where                   
the increasing of parasitemia was seen up to 16-22 
















Fig. 2. Parasitemia in blood of Swiss mouse post inoculation of 
attenuated P. berghei at several doses of gamma rays [39]. 
 
Whereas irradiation dose of 150-175 Gy were 
enable to suppress the infected erythrocyte cells and 
supported by the fact that long pre-patent, low 
parasitemia and lethality of mouse were found            
(Fig. 2) [39]. The second booster at two weeks after 
the first innoculation of 150 Gy irradiated 
plasmodium could elicit immune response and 
resulted in low density of plasmodium in the blood. 
The most effective malaria vaccine so far has 
been the irradiated sporozoite model. This vaccine, 
as it is now made, requires P. falciparum infected 
mosquitoes to be exposed to non-lethal levels of 
gamma irradiation sufficient to impair the 
development of the sporozoites in the salivary 
glands. This latter is currently conducted in BATAN 






Malaria remains one of the most devastating 
infectious diseases that threaten humankind.  Many 
scientists believe that the development and 
implementation of effective malaria vaccines, 
especially against the predominant species               
P. falciparum and P. vivax, will be critical to 
achieve malaria eradication. With malaria vaccines 
potentially within reach, it is important that the 
international community continue to support               
and increase investments in malaria vaccine 
research [12]. 
The first, and as yet unsurpassed, success in 
inducing protective immune responses against 
malaria was achieved with irradiated sporozoites 
in a rodent malaria model system Nussenzweig [24]. 
Immunization of mice with three doses of gamma-
irradiated sporozoites results in attenuated               
liver-stage development and elicits complete 
sustained protection against sporozoite challenge. 
Analogous to other live-attenuated vaccines, 
arrested plasmodium liver stages likely induce 
protective cell-mediated immune responses against 
the entire antigenic repertoire of the liver stage and 
may be the most potent malaria vaccine. Exposure 
of humans to radiation-attenuated P. falciparum 
sporozoites produced at multiple different sites was 
proven to elicit a high level of reproducible 
protective immunity in human volunteers at multiple 
locations. Much remains to be accomplished, but the 
path forward is clear. They are encouraged by               
the support of so many recognized experts in a               
wide spectrum of disciplines who have offered 
constructive advice and assistance to this nascent 


































Many factors make malaria vaccine 
development are challenging. The size and genetic 
complexity of the parasite mean that each infection 
presents thousands of antigens to the human 
immune system. The parasite also changes through 
several life stages even while in the human host, 
presenting different antigens (proteins) at different 
stages of its life cycle. For many infectious diseases 
it is possible to produce an attenuated (harmless) 
version of the pathogen or a pathogen subunit             
that will lead to protective immunity without 
causing disease. Although this is technically 
possible such as irradiated malaria sporozoites     
given by infected mosquito bite can lead to 
protective immunity, it is impractical to do this on a 
large scale [16]. 
In fact, although malaria vaccine development 
to date has met with only limited success, there             
are several lines of evidence that suggest that a 
malaria vaccine is possible: first, current                   
clinical studies have shown that new candidate 
vaccines can induce complete protection                    
against malaria infection;  second, complete 
protection against malaria can be induced by 
infecting volunteers with irradiated malaria 
parasites; third, people living in endemic areas who 
have been multiply exposed to malaria develop 
immunity against severe malaria disease; and fourth, 
antibodies purified from life-long residents of 
endemic areas can be transferred into other 
individuals and can confer some protection against 
the effects of malaria infection [40]. 
The genetic heterogeneity is one of the               
main causes of the difficulties in developing                   
an effective malaria vaccine. Segregation analysis 
identified that the nature of genetic factors                      
are involved in the expression of human diseases. 
Moreover, this genetic variant closely associated 
with almost 30 percent reduced risk of developing 
severe malaria. There is an increasing evidence                
of genetic predisposition to both susceptibility               
and outcome in this infectious disease. Emerging 
research also demonstrates that diet, pollution,               
and other environmental triggers can alter               
both the function and expression of human genes 
and lead to a heightened disease risk of malaria. 
Robust epidemiological evidence showed that host 
genetic factors are important determinants                   
of the outcome of interactions between host and 
pathogen. Genetic variation in the parasite is central 
to the pathogenesis of the organism, as allelic 
variability in different clones is thought to facilitate 
immune evasion. This in turn has significantly 
impeded progress towards the development of 
malaria vaccine [41]. Based on these facts,                     
the development of malaria vaccine should                     
be conducted regionally, not globally. Therefore it 
seems that we should develop our own malaria 
vaccine that is specific for Indonesian or at                
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